Welcome!
To use the personalized features of this site, please log in or register.
If you have forgotten your username or password, we can help.
My Menu
Saved Items

Symposium: Selected Papers Presented at the 2008 Meeting of the Musculoskeletal Tumor Society

Joint Preservation after Extensive Curettage of Knee Giant Cell Tumors

Miguel A. AyerzaContact Information, Luis A. Aponte-Tinao1, German L. Farfalli1, Carlos A. Lores Restrepo1 and D. Luis Muscolo1

(1)  Institute of Orthopedics “Carlos E. Ottolenghi,” Italian Hospital of Buenos Aires, Potosí 4247 (1199) Buenos Aires, Argentina

Received: 15 December 2008  Accepted: 20 May 2009  Published online: 10 June 2009

Abstract  Curettage is the most attractive procedure for surgically treating a giant cell tumor because it preserves joint function. However, since many giant cell tumors compromise subchondral bone this technique can jeopardize the articular surface with subsequent fractures or collapse. We asked whether intralesional curettage of a giant cell tumor close to the knee that combined morselized bone and cortical structural allograft would preserve joint function. We retrospectively reviewed 22 patients treated with that approach. The minimum followup was 2 years (average, 48 months; range, 24–80 months). The distal femur was involved in 12 patients and proximal tibia in 10. Complications and failures were recorded and functional results evaluated with Musculoskeletal Tumor Society score. We determined survivorship using the Kaplan-Meier technique using removal of the implant as the endpoint. The survival was 85% and the average functional score 28 points. Three of the 22 patients had a local tumor recurrence and one had a partial subchondral collapse not requiring further treatment. Among the remaining patients, none had fracture, infection, or knee instability. The combination of fragmented and cortical allograft allows reconstructing the bone defect and ligaments created after extensive curettage of a knee giant cell tumor obtaining normal joint function and a high survival rate with minimal complications in a high percentage of the patients.
Level of Evidence: Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.
Each author certifies that his institution has approved the reporting of this case report and that all investigations were conducted in conformity with ethical principles of research.

Contact Information Miguel A. Ayerza
Email: miguel.ayerza@hospitalitaliano.org.ar

References

1. Arbeitsgemeinschaft Knochentumoren, Becker WT, Dohle J, Bernd L, Braun A, Cserhati M, Enderle A, Hovy L, Matejovsky Z, Szendroi M, Trieb K, Tunn PU. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am. 2008;90:1060–1067.
CrossRef
 
2. Ayerza MA, Aponte-Tinao LA, Muscolo DL, Abalo ED. Morsellized and structural cortical allograft reconstruction after intralesional curettage of a distal femoral giant-cell tumor. Orthopedics. 2006;29:679–682.
PubMed
 
3. Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, Hardes J, Gosheger G. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134:969–978.
PubMed SpringerLink ChemPort
 
4. Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am. 1999;81:811–820.
PubMed CrossRef ChemPort
 
5. Buecker PJ, Gebhardt MC. Are fibula strut allografts a reliable alternative for periarticular reconstruction after curettage for bone tumors? Clin Orthop Relat Res. 2007;461:170–174.
PubMed
 
6. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am. 1987;69:106–114.
PubMed ChemPort
 
7. Eckardt JJ, Grogan TJ. Giant cell tumor of bone. Clin Orthop Relat Res. 1986;204:45–58.
PubMed
 
8. Enneking WF, Dunham W, Gebhardt MC, Malawer M, Prichard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241–246.
PubMed
 
9. Gitelis S, Mallin BA, Piasecki P, Turner F. Intralesional excision compared with en bloc resection for giant-cell tumor of bone. J Bone Joint Surg Am. 1993;75:1648–1655.
PubMed ChemPort
 
10. Glasser D, Langlais F. The ISOLS radiological implant evaluation system. In: Langlais F, Tomeno B, eds. Limb Salvage: Major Reconstructions in Oncologic and Nontumoral Conditions. Heidelberg, Germany: Springer-Verlag; 1991.
 
11. Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P, Follerås G. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008;79:86–93.
PubMed CrossRef
 
12. Li JM, Yang ZP, Li ZF, Li X, Carter SR. Knee reconstruction with preservation of the meniscus in tibial giant cell tumor. Clin Orthop Relat Res. 2008;466:3101–3107.
PubMed SpringerLink
 
13. Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y. Cryosurgery in the treatment of giant cell tumor: a long-term followup study. Clin Orthop Relat Res. 1999;359:176–188.
PubMed CrossRef
 
14. McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am. 1986;68:235–242.
PubMed ChemPort
 
15. Muscolo DL, Ayerza MA, Aponte-Tinao LA. Massive allograft use in orthopedic oncology. Orthop Clin North Am. 2006;37:65–74.
PubMed CrossRef
 
16. Muscolo DL, Ayerza MA, Calabrese ME, Gruenberg M. The use of a bone allograft for reconstruction after resection of giant-cell tumor close to the knee. J Bone Joint Surg Am. 1993;75:1656–1662.
PubMed ChemPort
 
17. Persson BM, Ekelund L, Lövdahl R, Gunterberg B. Favourable results of acrylic cementation for giant cell tumors. Acta Orthop Scand. 1984;55:209–214.
PubMed ChemPort
 
18. Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone? Clin Orthop Relat Res. 2005;435:211–218.
PubMed CrossRef
 
19. Schindler OS, Cannon SR, Briggs TW, Blunn GW. Use of a novel bone graft substitute in peri-articular bone tumours of the knee. Knee. 2007;14:458–464.
PubMed CrossRef
 
20. Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM. Giant cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. 1982;64:755–761.
PubMed ChemPort
 
21. Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM, Canadian Sarcoma Group. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res. 2002;397:248–258.
PubMed CrossRef
 
22. Ward WG Sr, Li G 3rd. Customized treatment algorithm for giant cell tumor of bone: report of a series. Clin Orthop Relat Res. 2002;397:259–270.
PubMed CrossRef
 
23. Zhen W, Yaotian H, Songjian L, Ge L, Qingliang W. Giant-cell tumour of bone: the long-term results of treatment by curettage and bone graft. J Bone Joint Surg Br. 2004;86:212–216.
PubMed CrossRef ChemPort
 


Export this article
Export this article as RIS | Text
 
Referenced by
1 newer article

  1. Cho, Hwan Seong (2009) Giant cell tumor of the femoral head and neck: result of intralesional curettage. Archives of Orthopaedic and Trauma Surgery
    [CrossRef]
Remote Address: 38.107.191.103 • Server: MPWEB25
HTTP User Agent: CCBot/1.0 (+http://www.commoncrawl.org/bot.html)